Review



ivig  (Kedrion Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Kedrion Inc ivig
    Cumulative reporting of most frequent ADRs with <t>this</t> <t>Kedrion</t> 5% <t>IVIg</t> by frequency and seriousness (1 January 1997–31 May 20254).
    Ivig, supplied by Kedrion Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ivig/ivig/pmc13019492-46-7-5
    Average 86 stars, based on 1 article reviews
    ivig - by Bioz Stars, 2026-09
    86/100 stars

    Images

    1) Product Images from "Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database"

    Article Title: Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database

    Journal: Current Therapeutic Research, Clinical and Experimental

    doi: 10.1016/j.curtheres.2026.100826

    Cumulative reporting of most frequent ADRs with this Kedrion 5% IVIg by frequency and seriousness (1 January 1997–31 May 20254).
    Figure Legend Snippet: Cumulative reporting of most frequent ADRs with this Kedrion 5% IVIg by frequency and seriousness (1 January 1997–31 May 20254).

    Techniques Used:

    Distribution of ADRs reported with this Kedrion 5% IVIg by age group and sex.
    Figure Legend Snippet: Distribution of ADRs reported with this Kedrion 5% IVIg by age group and sex.

    Techniques Used:

    Distribution of serious vs non-serious ADRs reported with this Kedrion 5% IVIg by age group and sex.
    Figure Legend Snippet: Distribution of serious vs non-serious ADRs reported with this Kedrion 5% IVIg by age group and sex.

    Techniques Used:

    Related Articles

    other:

    Article Title: Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database
    Article Snippet: Due to the use of different posologies for the various clinical conditions for which this Kedrion 5% IVIg is administered in clinical practice, this analysis is based on an estimate of average patient exposure to IVIg over the reference period.

    Article Title: Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database
    Article Snippet: Spontaneous post-marketing ADR reports for Kedrion 5% IVIg (January 1997–May 2025) were descriptively analyzed using the Kedrion Pharmacovigilance Database.

    Article Title: Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database
    Article Snippet: Distribution of ADRs reported with this Kedrion 5% IVIg by age group and sex.

    Article Title: Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database
    Article Snippet: Figure 2 dummy alt text Distribution of serious vs non-serious ADRs reported with this Kedrion 5% IVIg by age group and sex.

    Article Title: Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database
    Article Snippet: The Kedrion Pharmacovigilance Database (Veeva Vault Safety) investigated in this analysis contains safety records spanning more than 28 years (1 January 1997 to 31 May 2025) of clinical experience with this Kedrion 5% IVIg .

    Activity Assay:

    Article Title: Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database
    Article Snippet: .. This Kedrion 5% IVIg is approved for replacement therapy in the treatment of a variety of PIDs and SIDs, and in clinical settings in which the immunomodulatory activity of IVIg therapy has been shown to be beneficial: primary immune thrombocytopenia (ITP), Guillain Barré syndrome, Kawasaki disease (in conjunction with acetylsalicylic acid), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN). ..

    Concentration Assay:

    Article Title: Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database
    Article Snippet: This analysis confirms that the frequency of overall ADRs and potentially severe complications related to the administration of this Kedrion 5% IVIg are in line with previously published results from clinical trials and with its labelling., , , , , The ADRs reported in this database are consistent with the known safety profile of this specific agent in paediatric and adult populations., The formulation of this IVIg, which features a low concentration of IgA and maltose as a stabilising agent, is believed to contribute to the low rate of complications over the long timeframe evaluated. .. Additionally, the low frequency of TEEs reported with this Kedrion 5% IVIg is consistent with expectations based on the low residual concentration of factor XIa (below the limit of quantification of 0.25 mIU/mL) reported with this product. .. Glycosuria, which is usually mild and transient with no clinical signs, has been observed after administration of this Kedrion 5% IVIg in paediatric patients.



    Similar Products

    ivig  (Wolters Kluwer Health)
    86
    Wolters Kluwer Health ivig
    Ivig, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ivig/ivig/10__1097_slash_tp__0000000000005772-609-31-2
    Average 86 stars, based on 1 article reviews
    ivig - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    ivig  (Kedrion Inc)
    86
    Kedrion Inc ivig
    Cumulative reporting of most frequent ADRs with <t>this</t> <t>Kedrion</t> 5% <t>IVIg</t> by frequency and seriousness (1 January 1997–31 May 20254).
    Ivig, supplied by Kedrion Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ivig/ivig/pmc13019492-46-7-5
    Average 86 stars, based on 1 article reviews
    ivig - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    ivig product  (Kedrion Inc)
    86
    Kedrion Inc ivig product
    Cumulative reporting of most frequent ADRs with <t>this</t> <t>Kedrion</t> 5% <t>IVIg</t> by frequency and seriousness (1 January 1997–31 May 20254).
    Ivig Product, supplied by Kedrion Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ivig/ivig/pmc13019492-98-20-18
    Average 86 stars, based on 1 article reviews
    ivig product - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Cumulative reporting of most frequent ADRs with this Kedrion 5% IVIg by frequency and seriousness (1 January 1997–31 May 20254).

    Journal: Current Therapeutic Research, Clinical and Experimental

    Article Title: Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database

    doi: 10.1016/j.curtheres.2026.100826

    Figure Lengend Snippet: Cumulative reporting of most frequent ADRs with this Kedrion 5% IVIg by frequency and seriousness (1 January 1997–31 May 20254).

    Article Snippet: Spontaneous post-marketing ADR reports for Kedrion 5% IVIg (January 1997–May 2025) were descriptively analyzed using the Kedrion Pharmacovigilance Database.

    Techniques:

    Distribution of ADRs reported with this Kedrion 5% IVIg by age group and sex.

    Journal: Current Therapeutic Research, Clinical and Experimental

    Article Title: Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database

    doi: 10.1016/j.curtheres.2026.100826

    Figure Lengend Snippet: Distribution of ADRs reported with this Kedrion 5% IVIg by age group and sex.

    Article Snippet: Spontaneous post-marketing ADR reports for Kedrion 5% IVIg (January 1997–May 2025) were descriptively analyzed using the Kedrion Pharmacovigilance Database.

    Techniques:

    Distribution of serious vs non-serious ADRs reported with this Kedrion 5% IVIg by age group and sex.

    Journal: Current Therapeutic Research, Clinical and Experimental

    Article Title: Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database

    doi: 10.1016/j.curtheres.2026.100826

    Figure Lengend Snippet: Distribution of serious vs non-serious ADRs reported with this Kedrion 5% IVIg by age group and sex.

    Article Snippet: Spontaneous post-marketing ADR reports for Kedrion 5% IVIg (January 1997–May 2025) were descriptively analyzed using the Kedrion Pharmacovigilance Database.

    Techniques:

    Cumulative reporting of most frequent ADRs with this Kedrion 5% IVIg by frequency and seriousness (1 January 1997–31 May 20254).

    Journal: Current Therapeutic Research, Clinical and Experimental

    Article Title: Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database

    doi: 10.1016/j.curtheres.2026.100826

    Figure Lengend Snippet: Cumulative reporting of most frequent ADRs with this Kedrion 5% IVIg by frequency and seriousness (1 January 1997–31 May 20254).

    Article Snippet: Of note, 1,758 ADRs were associated with individual cases in which the reported brand name corresponded to a Kedrion-manufactured 5% IVIg product included in this analysis.

    Techniques:

    Distribution of ADRs reported with this Kedrion 5% IVIg by age group and sex.

    Journal: Current Therapeutic Research, Clinical and Experimental

    Article Title: Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database

    doi: 10.1016/j.curtheres.2026.100826

    Figure Lengend Snippet: Distribution of ADRs reported with this Kedrion 5% IVIg by age group and sex.

    Article Snippet: Of note, 1,758 ADRs were associated with individual cases in which the reported brand name corresponded to a Kedrion-manufactured 5% IVIg product included in this analysis.

    Techniques:

    Distribution of serious vs non-serious ADRs reported with this Kedrion 5% IVIg by age group and sex.

    Journal: Current Therapeutic Research, Clinical and Experimental

    Article Title: Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database

    doi: 10.1016/j.curtheres.2026.100826

    Figure Lengend Snippet: Distribution of serious vs non-serious ADRs reported with this Kedrion 5% IVIg by age group and sex.

    Article Snippet: Of note, 1,758 ADRs were associated with individual cases in which the reported brand name corresponded to a Kedrion-manufactured 5% IVIg product included in this analysis.

    Techniques: